Blockchain Press Releases
Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation
- Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients in Europe die annually from the disease²
- If approved by the European Commission, ORSERDU would be the first and only treatment specifically indicated for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations
- ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers, and are a known driver of resistance to standard endocrine therapy, making these tumors more difficult to treat
FLORENCE, Italy and NEW YORK, July 21, 2023 /PRNewswire/ — The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the approval of ORSERDU® (elacestrant) monotherapy, indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)–positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.
The CHMP opinion will now be reviewed by the European Commission, which has the authority to grant marketing authorization for human medicines throughout the European Union (EU). If approved, Stemline and its affiliates will commercialize the product within Europe. ORSERDU would be the first and only therapy specifically indicated for the treatment of ER+, HER2- tumors that harbor ESR1 mutations. ESR1 mutations are acquired mutations that develop as a result of exposure to endocrine therapy, and they are found in up to 40% of patients with ER+, HER2- mBC. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and until now, the tumors that harbor these mutations have been more difficult to treat.
“Patients living with metastatic breast cancer are in need of efficacious and tolerable treatment options. ORSERDU may become the first product, if approved by the European Commission, indicated in ER+, HER2- advanced breast cancer with ESR1 mutations, which are a strong driver of resistance to treatment in up to 40% of patients in second line mBC. ORSERDU, if approved, will also provide a convenient daily oral treatment,” said Elcin Barker Ergun, CEO of the Menarini Group. “We are proud of today’s positive CHMP opinion as it reflects our commitment to developing innovative solutions that address the greatest unmet needs in cancer treatment, and brings us one step closer to providing an important new option to the patients and families impacted by ESR1-mutated, ER+, HER2- metastatic breast cancer.”
The positive CHMP opinion for ORSERDU is supported by data from the Phase 3 EMERALD trial, which demonstrated statistically significant progression-free survival (PFS) with elacestrant versus standard-of-care (SOC), defined as investigator’s choice of an approved endocrine monotherapy. The primary endpoints of the study were PFS in the overall patient population and in patients with ESR1 mutations. In the group of patients whose tumors had ESR1 mutations, elacestrant achieved a median PFS of 3.8 months vs 1.9 months on the SOC, and reduced the risk of progression or death by 45% (PFS HR=0.55, 95% CI: 0.39, 0.77) vs SOC.
A post hoc subgroup analysis of the EMERALD PFS results, which were presented at the San Antonio Breast Cancer Symposium (SABCS) 2022, demonstrated that the duration of prior CDK4/6i treatment was positively associated with longer PFS on elacestrant but not with SOC. For patients with ESR1 mutations who were treated with CDK4/6i for ≥12 months prior to randomization on EMERALD, elacestrant achieved a median PFS of 8.6 months versus 1.9 months on SOC, with a 59% reduction in the risk of progression or death (HR=0.41 95% CI: 0.26-0.63).³
“As an oncologist, it is remarkable that we are on the cusp of having the first treatment option for patients with advanced or metastatic ER+, HER2- breast cancer harboring ESR1 mutations, which occur in up to 40% of patients in the metastatic setting,” said Giuseppe Curigliano, MD, PhD, Professor of Medical Oncology at the University of Milano and the Head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy. “Elacestrant has demonstrated efficacy and a manageable safety profile, underscoring the potential benefit this therapy may soon bring to the patients we care for, and to the broader oncology community.”
Safety data were consistent with previously reported results. Serious adverse reactions reported in ≥ 1% of patients included nausea, dyspnoea, and thromboembolism (venous). The most common (≥ 10%) adverse reactions with ORSERDU were nausea, triglycerides increased, cholesterol increased, vomiting, fatigue, dyspepsia, diarrhoea, calcium decreased, back pain, creatinine increased, arthralgia, sodium decreased, constipation, headache, hot flush, abdominal pain, anaemia, potassium decreased, and alanine aminotransferase increased. The most common Grade ≥3 (≥2%) adverse reactions of elacestrant were nausea (2.7%), AST increased (2.7%), ALT increased (2.3%), anaemia (2%), back pain (2%), and bone pain (2%).
About the EMERALD Phase 3 Study (NCT03778931)
The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+, HER2- advanced/metastatic breast cancer patients. The study enrolled 478 patients who had received prior treatment with one or two lines of endocrine therapy, including a CDK4/6 inhibitor. Patients in the study were randomized to receive either elacestrant or the investigator’s choice of an approved hormonal agent. The primary endpoints of the study were progression-free survival (PFS) in the overall patient population and in patients with estrogen receptor 1 gene (ESR1) mutations. In the group of patients whose tumors had ESR1 mutations, elacestrant achieved a median PFS of 3.8 months vs 1.9 months on the SOC, and reduced the risk of progression or death by 45% (PFS HR=0.55, 95% CI: 0.39, 0.77) vs SOC.
Elacestrant is also being investigated in several clinical trials in metastatic breast cancer disease, alone or in combination with other therapies: ELEVATE (NCT05563220); ELECTRA (NCT05386108); and ELCIN (NCT05596409). Elacestrant is also planned to be evaluated in early breast cancer disease.
The Menarini Group obtained global licensing rights for elacestrant in July 2020 from Radius Health, Inc. The Menarini Group is now fully responsible for global registration, commercialization, and further development activities for elacestrant.
About The Menarini Group
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4.4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit www.menarini.com.
About Stemline Therapeutics Inc.
Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes ORSERDU® (elacestrant) in the United States, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline also commercializes ELZONRIS® (tagraxofusp-erzs), a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States and Europe, which is the only approved treatment for BPDCN in the US and EU to date. Stemline also commercializes Nexpovio® in Europe, an XPO1 inhibitor for multiple myeloma. Stemline also has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers.
¹ Decision Resource Group / Clarivate Breast Cancer Landscape / Epidemiology – June 14, 2023
² International Agency for Research on Cancer, World Health Organization – Globocan – 2020
³ Bardia et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting. SABCS 2022. GS3-01
Logo – https://mma.prnewswire.com/media/1958938/MENARINI_GROUP_Logo.jpg
SINGAPORE, March 19, 2025 /PRNewswire/ — AB DAO has officially announced a strategic partnership with Alpha Technology Group Limited (Nasdaq: ATGL). The two companies will integrate their respective strengths to drive the innovative application and adoption of artificial intelligence (AI) and blockchain technology across supply chain management, enterprise operations, and the Internet of Things (IoT).
Alpha Technology Group Limited (ATGL), listed on the Nasdaq in 2023, specializes in AI technology development. Its AI-powered enterprise resource planning (ERP) systems provide intelligent automation solutions, significantly enhancing corporate management efficiency.
AB DAO, a leading AI-driven blockchain infrastructure provider, has designed the AB IoT network specifically to integrate blockchain and IoT technologies. It has already developed mature prototype products, including blockchain-powered smart energy meters, self-service payment kiosks, access control systems, and secure storage solutions, demonstrating strong market potential across various industries.
With complementary strengths in both technology and market positioning, this partnership will focus on advancing AI and blockchain integration in logistics, supply chain, and enterprise management. By delivering more efficient and secure industry solutions, AB DAO and ATGL aim to accelerate innovation and achieve mutual success.
(Alpha Technology Group Limited Official Website: www.atgl.io)
AB DAO Ecosystem Continues to Expand
With the Hotcoin listing, users can now trade $AB on the following exchanges:
Bitget (bitget.com)
HTX (htx.com)
MEXC (mexc.com)
BingX (bingx.com)
BitMart (bitmart.com)
Lbank (lbank.com)
Hotcoin (hotcoin.com)
UEEx(ueex.com)
4E (eeee.com)
Coming Soon
Biconomy (biconomy.com)
AB will continue listing on more exchanges, expanding its ecosystem use cases and accelerating worldwide adoption.
AB DAO’s Goal: 100 Million $AB Holders
Stay Updated with AB DAO
Official Website: https://ab.org
Telegram Global Community: https://t.me/Newtonproject
Telegram Chinese Community: http://t.me/ABgonglian
Telegram English Channel: https://t.me/AB202528
X (Twitter): https://x.com/ABDAO_Global
Discord: https://discord.gg/BSbgK6J
View original content:https://www.prnewswire.co.uk/news-releases/ab-dao-partners-with-alpha-technology-to-pioneer-the-aiblockchain-era-302405710.html
Blockchain Press Releases
MEXC Dominates Token Listings with Highest Success Rate and Speed – TokenInsight Report
VICTORIA, Seychelles, March 19, 2025 /PRNewswire/ — MEXC, a global cryptocurrency exchange, has reaffirmed its leadership in token listings, surpassing competitors in speed, volume, and market positioning, according to the latest TokenInsight Crypto Exchange report. Covering the period from November 1, 2024, to February 15, 2025, the report provides key insights into how centralized exchanges (CEXs) adapt to shifting market narratives during the latest bull run and how these changes influence their listing strategies.
Key Takeaways
- MEXC ranked first in spot listings, with 461 new tokens added.
- The report recognized MEXC as a “Trend Capturer,” citing the strong performance of its early-listed tokens.
- MEXC led in the conversion success rate (82.46%) for memecoin listings.
- The exchange listed TRUMP just 2 hours and 20 minutes after its initial on-chain liquidity injection—far ahead of competitors.
- MEXC was among the first exchanges to list major trend-driven tokens, including PNUT, CHILLGUY, AIXBT, BIO, RIFSOL, TRUMP, and VINE.
MEXC Leads in Token Listings and Market Agility
Over the past three months, MEXC has listed 461 new spot trading pairs—1.5 times more than Gate.io and 4.5 times more than Bitget—demonstrating its superior ability to capture market momentum. The exchange has maintained a consistent two-week listing cycle, ensuring that traders gain early access to promising assets before they reach mainstream markets.
This agility is particularly evident in key industry trends, as MEXC has emerged as the first major exchange to list tokens tied to the four dominant narratives of the current market: Meme, DeSci, AI Agent, and Celebrity Tokens.
A Leader in Early Listings
The TokenInsight report recognizes MEXC as a “Trend Capturer” for positioning its traders ahead of major market moves. By listing tokens early in their lifecycle, the exchange enables traders to capitalize on rapid growth opportunities.
For example, CHILLGUY was listed when its market cap was below $150 million and surged to $600 million within just ten days. MEXC’s reputation for early-market foresight has been reinforced by its rapid listing of high-performing tokens, including PNUT, CHILLGUY, AIXBT, BIO, RIFSOL, TRUMP, and VINE. Many of these tokens experienced significant price surges post-listing.
A standout case is TRUMP, which MEXC listed on January 18 at 03:20 UTC, just 2 hours and 20 minutes after its initial on-chain liquidity injection—well ahead of other exchanges, which didn’t follow until after 10:00 UTC. This ultra-fast turnaround underscores MEXC’s sharp market responsiveness, allowing traders to access high-momentum tokens before broader adoption.
Quality in On-Chain Listings
Unlike platforms that focus solely on token volume, MEXC takes a selective approach, prioritizing high-potential on-chain assets. TokenInsight’s data reveals that MEXC’s 82.46% conversion rate from on-chain listings to its primary spot market far surpasses Gate.io’s 11.76%, highlighting its ability to identify sustainable projects.
Largest Market Share and Top 5 CEX Ranking
With its ability to identify and list emerging trends faster than competitors, MEXC continues to solidify its position among top-tier exchanges. Beyond leading in new listings, CoinDesk data confirms that MEXC captured the largest market share among centralized exchanges in February 2025 and secured a top-five ranking based on overall market share.
The full report is available on TokenInsight’s official website.
About MEXC
Founded in 2018, MEXC is dedicated to being “Your Easiest Way to Crypto.” Known for its extensive selection of trending tokens, airdrop opportunities, and low fees, MEXC serves over 34 million users across 170+ countries. With a focus on accessibility and efficiency, our advanced trading platform appeals to both new traders and seasoned investors alike. MEXC provides a seamless, secure, and rewarding gateway to the world of digital assets.
For more information, visit: MEXC Website | X | Telegram | How to Sign Up on MEXC
About TokenInsight
TokenInsight is a leading research and data analytics firm focused on the cryptocurrency and blockchain industry. Through detailed market reports and data-driven insights, TokenInsight provides actionable intelligence to investors, exchanges, and industry participants.
Photo – https://mma.prnewswire.com/media/2645125/1920×1080.jpg
Logo – https://mma.prnewswire.com/media/2645195/MEXC_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/mexc-dominates-token-listings-with-highest-success-rate-and-speed–tokeninsight-report-302405695.html
Blockchain Press Releases
HTX Research Analysis: Bittensor’s dTAO Upgrade Redefines Decentralized AI Infrastructure
SINGAPORE, March 19, 2025 /PRNewswire/ — HTX Research, the research arm of HTX Group, has released an in-depth report titled, “dTAO and the Evolution of Bittensor: Reshaping Decentralized AI with Market-Driven Incentives.”. The evolution of artificial intelligence has transitioned from foundational model development to the refinement and optimization of existing systems, a trend exemplified by industry leaders such as DeepSeek and OpenAI. This analysis examines how Bittensor’s Dynamic TAO (dTAO) upgrade addresses inherent challenges within decentralized AI, positioning the network as a pioneering force in this emerging sector.
Bittensor’s Architecture: Foundation for a Decentralized AI Ecosystem
Bittensor’s architecture is structured around three core components: the Subtensor blockchain, a Polkadot parachain with EVM compatibility; 64 specialized subnets; and a governance-focused Root Subnet. The network employs a dual-key security system, Coldkey-Hotkey, and a subnet UID framework to facilitate secure and open participation for miners and validators. At the core of its operational model is the Yuma Consensus (YC), a dynamic incentive mechanism that diverges from traditional static reward systems. YC assesses validators’ weight vectors, derived from historical performance and stake, to distribute TAO rewards every 12 seconds, establishing a self-regulating “stake → weight → reward” loop. This mechanism aligns contributions with incentives while mitigating malicious activities through continuous adjustments.
The dTAO Upgrade: Market-Driven Resource Allocation
The dTAO upgrade, implemented on February 13, 2025, introduces liquidity pools for subnet tokens, fundamentally altering Bittensor’s economic framework. Key innovations include:
- Subnet Token Liquidity Pools: Each subnet’s dTAO tokens are paired with TAO in automated market-maker pools, enabling price discovery driven by supply-demand dynamics.
- Emission Rebalancing: 50% of new subnet emissions are injected into liquidity pools, incentivizing long-term participation.
- Validator-as-VC Dynamics: Validators now act as venture capitalists, strategically staking TAO into high-potential subnets to maximize returns.
This upgrade addresses previous systemic limitations, such as validator centralization, resource redundancy, and misaligned incentives. By linking subnet rewards to market performance, dTAO fosters competition, encouraging the development of specialized AI solutions, ranging from multimodal content detection to decentralized search engines.
Ecosystem Impact: Emergence of High-Performance Subnets
The implementation of dTAO has led to the emergence of high-performing subnets, operating within a self-reinforcing feedback loop where increasing token prices attract greater TAO emissions, subsequently drawing more users and validators. Examples include:
- Chutes: A CLI toolkit for deploying decentralized apps, Chutes’ subnet token surged rapidly, driven by its integration with Bittensor’s Subnets 19 and 56.
- Multi Modality (Subnet 4): Focused on AI-generated content detection, this subnet leverages balanced validator-miner challenges to ensure model accuracy.
However, projects like Kaito highlight potential pitfalls, demonstrating that technical proficiency alone does not guarantee success without robust integration with core product utility.
Despite the advancements introduced by dTAO, HTX Research also identifies ongoing challenges, including the lack of real-world demand drivers for TAO rewards, the potential for resource redundancy among overlapping subnets, and persistent validator centralization. To ensure sustained growth, HTX Research emphasizes the necessity for on-chain verifiability, standardized subnet performance benchmarking systems, and the integration of subnet token utility, such as governance or service access, to reduce speculative trading.
Bittensor’s dTAO upgrade signifies a transition from centralized governance to market-driven incentives. While challenges remain, the network’s architecture and economic model provide a solid foundation for decentralized AI innovation. As subnet tokens evolve into tools with tangible utility, Bittensor is positioned to redefine collaborative and competitive dynamics within AI ecosystems.
HTX Research remains committed to providing comprehensive analyses of these developments, offering actionable insights into the intersection of AI and blockchain technology. For the complete report, please visit Here.
About HTX Research:
HTX Research is the dedicated research arm of HTX Group, responsible for conducting in-depth analyses, producing comprehensive reports, and delivering expert evaluations across a broad spectrum of topics, including cryptocurrency, blockchain technology, and emerging market trends. Committed to providing data-driven insights and strategic foresight, HTX Research plays a pivotal role in shaping industry perspectives and supporting informed decision-making within the digital asset space. Through rigorous research methodologies and cutting-edge analytics, HTX Research remains at the forefront of innovation, driving thought leadership and fostering a deeper understanding of evolving market dynamics.
Contact: [email protected]
Photo – https://mma.prnewswire.com/media/2645188/HTX.jpg
Logo – https://mma.prnewswire.com/media/2391903/image_ID__Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/htx-research-analysis-bittensors-dtao-upgrade-redefines-decentralized-ai-infrastructure-302405636.html
-
Blockchain6 days agoBlocks & Headlines: Today in Blockchain – March 13, 2025: Featuring XRPTurbo, Ripple, DFSA, 75th USARIC, Allianz
-
Blockchain Press Releases5 days agoMEXC Lists AO (AO), Expanding Support for Decentralized Computing and AI Innovation with a 140,000 USDT Prize Pool
-
Blockchain7 days ago
Blocks & Headlines: Today in Blockchain – March 12, 2025 | Blockchain Week Rome, Sony Integration, DC Blockchain Summit, Base, BingX
-
Blockchain5 days ago
Concerned Stockholders Prevail in Delaware Court; Obtain Stockholder List Necessary for Robust Proxy Solicitation
-
Blockchain Press Releases7 days agoAB DAO Accelerates Global Expansion: Now AB Listed on BitMart & HTX AMA to Explore the Future of Web3
-
Blockchain Press Releases6 days ago
HTX Ventures: DeepSeek Triggers AI’s “iPhone Moment”, Accelerating AI Agents into Real Crypto Use
-
Blockchain Press Releases6 days agoDeriW Testnet Launch Sets New Standards in Decentralized Derivatives Trading
-
Blockchain7 days agoCrypto Cards Go Non-Custodial With GoDefi, Announces Second Funding Round Following Initial Launch Success
